Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary

by Institute of Medicine, Board on Health Sciences Policy, Forum on Drug Discovery Development and Translation, et al.

To effectively treat patients diagnosed with drug-resistant (DR) tuberculosis (TB) and protect the population from further transmission of this infectious disease, an uninterrupted supply of quality-assured (QA), second-line anti-TB drugs (SLDs) is necessary. Patients diagnosed with multidrug-resistant tuberculosis (MDR TB)--a disease caused by strains of Mycobacterium tuberculosis (M.tb.) resistant to two primary TB drugs (isoniazid and rifampicin)--face...

• Format: Paperback
• Language: English
• ISBN: 0309265959
• ISBN13: 9780309265959
• Release Date: March 2013
• Publisher: National Academies Press
• Length: 170 Pages
• Weight: 0.75 lbs.
• Dimensions: 0.5" x 6.0" x 8.9"